This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (November 2021)
Emergent BioSolutions Inc.
Company type
Public company
Traded as
NYSE: EBS
Russell 2000 component
Founded
September 5, 1998; 25 years ago (1998-09-05) (as BioPort Inc.)
Founder
Fuad El-Hibri
Headquarters
Gaithersburg, Maryland, U.S.
Key people
Haywood Miller (interim CEO) Zsolt Harsanyi (Chairman)
Revenue
US$1.793 billion (2021)[1]
Operating income
US$352.6 million (2021)[1]
Net income
US$230.9 million (2021)[1]
Number of employees
2,416 (December 31, 2021)[1]
Website
www.emergentbiosolutions.com
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland.[2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax (Anthrax Vaccine Adsorbed),[3] the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA) and Narcan (naloxone) for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.
^ abcd"2021 Annual Report". Emergent BioSolutions. Retrieved February 14, 2023.
^Claybaugh, Jeff (August 30, 2018). "Gaithersburg company buys Narcan maker". WTOP News Radio. Washington, DC: Hubbard Radio. Retrieved March 27, 2019.
^Hamby, Chris; Stolberg, Sheryl Gay (March 6, 2021). "How One Firm Put an 'Extraordinary Burden' on the U.S.'s Troubled Stockpile". The New York Times. Retrieved January 15, 2022.
and 22 Related for: Emergent BioSolutions information
EmergentBioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines...
Simulation Software EmergentBioSolutions, a multinational biopharmaceutical company headquartered in Gaithersburg, Maryland, USA Emergent properties, when...
to Emergent until 2015. Soon after taking office, Kadlec pushed to increase the government's stockpile of smallpox vaccine from EmergentBioSolutions, and...
Heptavalent (A, B, C, D, E, F, G) - (Equine) (trade name BAT), made by EmergentBioSolutions Canada Inc. (formerly Cangene Corporation) – is a licensed, commercially...
United States. p. 8. "EmergentBioSolutions Completes Acquisition of Cangene Corporation" (Press release). EmergentBioSolutions. 21 February 2014. Retrieved...
risks of residual anthrax spores in the workplace. BioPort changed its name to EmergentBioSolutions in 2004. Despite the positive IOM assessment, mandatory...
Coronavirus Crisis during the May 19, 2021, hearings involving EmergentBioSolutions founder Faud El-Hibiri and its CEO Robert G. Kramer. In the aftermath...
military and certain civilian personnel with BioThrax, an anthrax vaccine manufactured by EmergentBioSolutions Inc. It was set up by the Clinton administration...
emerging infectious diseases. EmergentBioSolutions manufactures the only FDA licensed vaccine against anthrax disease, called BioThrax, which is recommended...
heptavalent botulism antitoxin (BAT) from the American-based company EmergentBiosolutions, a global specialty biopharmaceutical company. The PHAC has identified...
autoimmune and inflammatory diseases and cancer. Trubion was acquired by EmergentBioSolutions on October 28, 2010. Trubion was established in 1999 in the State...
purchased by GlaxoSmithKline (GSK). In 2017, it was acquired by EmergentBioSolutions The most commonly observed adverse events are headaches, upper respiratory...
on 12 January 2018. Retrieved 4 July 2022. EmergentBioSolutions (3 September 2019). "EmergentBioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®...
of directors of EmergentBioSolutions, a biotechnology company, after a referral to the post by Allen Shofe, an executive at Emergent. His other post-military...
effects of this vaccine are mild and rare. Vivotif (manufactured by EmergentBioSolutions) Ty21a may also provide some degree of protection against paratyphoid...
is purified and produced using modern cell culture technology. EmergentBioSolutions developed ACAM2000 under a contract with the U.S. Centers for Disease...
Genetics, Johnson & Johnson, and Bavarian Nordic. Another company, EmergentBioSolutions, was a contestant for manufacturing new doses of ZMapp,[citation...
designed for the treatment of cancer. This drug was developed by EmergentBioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic...
August 20, 2011. Retrieved August 19, 2011. "EmergentBioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax...
the original on 1 April 2019. Retrieved 2 April 2019. Gilgore S. "EmergentBioSolutions defends opioid overdose drug against generic competitor". Archived...
Global Information
